Horizon Discovery drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.



  • CSC team worked closely with Horizon since IPO in 2014

  • Supporting corporate activity including 2014 IPO, acquisition of Dharmacon and other M&A, defence against hostile takeover attempt, leadership changes, divestment of business units



  • Develop and implement all external and internal communications strategies and materials including for key international trade and
  • Close work with management and board, providing sounding-board
  • Media relations: relationships developed with key nationals, business and investment press
  • Analyst relations: strong rapport built with covering & interested international analysts, regular calls and events held to maintain those relationships



  • Horizon is recognized as a leader in gene editing and modulation in the UK and internationally

  • Recommended all cash offer of £296m from PerkinElmer